ME00959B - Farmaceutska kompozicija sa sporim oslobađanjem koja je formirana od mikročestica - Google Patents
Farmaceutska kompozicija sa sporim oslobađanjem koja je formirana od mikročesticaInfo
- Publication number
- ME00959B ME00959B MEP-2009-341A MEP34109A ME00959B ME 00959 B ME00959 B ME 00959B ME P34109 A MEP34109 A ME P34109A ME 00959 B ME00959 B ME 00959B
- Authority
- ME
- Montenegro
- Prior art keywords
- microparticles
- pharmaceutical composition
- composition according
- group
- specified
- Prior art date
Links
- 239000011859 microparticle Substances 0.000 title claims abstract 14
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 14
- 239000000203 mixture Substances 0.000 claims abstract 9
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract 8
- 229920001577 copolymer Polymers 0.000 claims abstract 5
- 238000002347 injection Methods 0.000 claims abstract 5
- 239000007924 injection Substances 0.000 claims abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 5
- 150000003839 salts Chemical class 0.000 claims abstract 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims abstract 4
- 239000013543 active substance Substances 0.000 claims abstract 4
- 235000014655 lactic acid Nutrition 0.000 claims abstract 4
- 239000004310 lactic acid Substances 0.000 claims abstract 4
- 229920000642 polymer Polymers 0.000 claims abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Farmaceutska kompozicija napravljena od mikročestica za sporo oslobađanje aktivne supstance najmanje tokom perioda koji pokriva šesti mesec posle injektiranja navedene kompozicije, pri čemu navedena kompozicija sadrži grupu mikročestica napravljenih od kopolimera PLGA tipa koji sadrži aktivnu supstancu u obliku peptidne soli koja je nerastvorljiva u vodi; pri čemu navedeni kopolimer pored toga sadrži najmanje 75% mlečne kiseline i ima viskoznost između 0.1 i 0.9 dl/g, kao što je mereno u hloroformu na 25°C i pri koncentraciji polimera od 0.5 g/dL; navedene mikročestice pored toga imaju raspodelu veličine defmisanu na sledeći način: -D (v, 0.1) je između 10 i 30 mikrometara, - D (v, 0.5) je između 30 i 70 mikrometara, - D (v, 0.9) je između 50 i 110 mikrometara.
Claims (15)
1. Farmaceutska kompozicija napravljena od mikročestica za sporo oslobađanje aktivne supstance najmanje tokom perioda koji pokriva 6-ti mesec posle injekcije navedene kompozicije, pri čemu navedena kompozicija sadrži grupu mikročestica napravljenih od kopolimera PLGA tipa koja obuhvata aktivnu supstancu u obliku peptidne soli koja je nerastvorljiva u vodi; navedeni kopolimer dalje sadrži najmanje 75% mlečne kiseline i ima viskoznost između 0.1 i 0.9 dl/g, kao što je mereno u hloroformu na 25°C i pri koncentraciji polimera od 0.5 g/dL; navedene mikročestice dalje imaju raspodelu veličine definisanu na sledeći način: -D (v, 0.1) je između 10 i 30 mikrometara, - D (v, 0.5) je između 30 i 70 mikrometara, - D (v, 0.9) je između 50 i 110 mikrometara.
2.Farmaceutska kompozicija prema patentnom zahtevu l, naznačena time što je količina mlečne kiseline od najmanje 85%.
3.Farmaceutska kompozicija prema patentnom zahtevu 2, naznačena time što je viskoznost između 0.1 i 0.4 dl/g.
4.Farmaceutska kompozicija prema patentnom zahtevu 2, naznačena time što je navedena viskoznost između 0.55 i 0.75 dl/g i poželjnije između 0.63 i 0.67 dl/g.
5.Farmaceutska kompozicija prema bilo kom od prethodnih patentnih zahteva, naznačena time što su navedene mikročestice mikrosfere.
6.Farmaceutska kompozicija prema bilo kom od prethodnih patentnih zahteva l do 4, naznačena time što su navedene mikročestice mikrogranule.
7.Farmaceutska kompozicija prema bilo kom od prethodnih patentnih zahteva, naznačena time što dalje sadrži drugu grupu mikročestica napravljenu od kopolimera PLGA tipa koji obuhvata navedenu aktivnu supstancu i koji sadrži količinu mlečne kiseline od između 70% i 80%.
8.Farmaceutska kompozicija prema patentnom zahtevu 7, naznačena time što je viskoznost navedene druge grupe između 0.60 i 0.70 dl/g.
9.Farmaceutska kompozicija prema patentnom zahtevu 8, naznačena time što su mikročestice navedene druge grupe mikrogranule.
10.Farmaceutska kompozicija prema bilo kom od prethodnih patentnih zahteva 7 do 9, naznačena time što su obe grupe u odnosu doze 50:50.
11.Farmaceutska kompozicija prema bilo kom od prethodnih patentnih zahteva, naznačena time što je najmanje jedna navedena grupa mikročestica dobijena mešanjem navedenog PLGA sa navedenom peptidnom soli koja je nerastvorljiva u vodi, u postupku bez rastvarača.
12.Primena farmaceutske kompozicije prema bilo kom od patentnih zahteva l do 6 za sporo oslobađanje peptidne soli koja je nerastvorljiva u vodi, tokom perioda počevši od najmanje 4-tog meseca posle injekcije navedene kompozicije do i uključujući 6-ti mesec.
13.Primena prema patentnom zahtevu 12, naznačena time što navedeni period počinje od prvog meseca posle injekcije navedene kompozicije.
14.Primena prema patentnom zahtevu 12 ili 13, naznačena time što dalje sadrži primenu druge grupe mikročestica kao što je definisano u bilo kom od patentnih zahteva 7 do ll, navedene mikročestice druge grupe dizajnirane su za oslobađanje navedene peptidne soli koja je nerastvorljiva u vodi tokom najmanje prva tri meseca posle injekcije navedene kompozicije.
15.Primena kompozicije prema bilo kom od prethodnih patentnih patentnih zahteva l do ll za pripremu leka za lečenje kancera prostate, naznačena time što se navedena kompozicija primenjuje jednom na svakih 6 meseci.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07109767 | 2007-06-06 | ||
| IB2007054372 | 2007-10-27 | ||
| PCT/IB2008/052241 WO2008149320A2 (en) | 2007-06-06 | 2008-06-06 | Slow release pharmaceutical composition made of microparticles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME00959B true ME00959B (me) | 2012-06-20 |
Family
ID=40032512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2009-341A ME00959B (me) | 2007-06-06 | 2008-06-06 | Farmaceutska kompozicija sa sporim oslobađanjem koja je formirana od mikročestica |
Country Status (32)
| Country | Link |
|---|---|
| US (4) | US10166181B2 (me) |
| EP (3) | EP2500014B2 (me) |
| JP (1) | JP5419169B2 (me) |
| KR (1) | KR101631475B1 (me) |
| CN (1) | CN101677959B (me) |
| AP (1) | AP3000A (me) |
| AU (1) | AU2008259411B2 (me) |
| BR (1) | BRPI0812250B8 (me) |
| CA (1) | CA2688478C (me) |
| CO (1) | CO6251234A2 (me) |
| CY (2) | CY1118434T1 (me) |
| DK (2) | DK2500014T4 (me) |
| EA (1) | EA019284B1 (me) |
| ES (2) | ES2694401T5 (me) |
| FI (1) | FI2500014T4 (me) |
| HR (2) | HRP20161785T1 (me) |
| HU (2) | HUE040391T2 (me) |
| IL (1) | IL202501A (me) |
| LT (2) | LT2500014T (me) |
| MA (1) | MA31422B1 (me) |
| ME (1) | ME00959B (me) |
| MX (1) | MX2009012856A (me) |
| MY (1) | MY150450A (me) |
| NZ (1) | NZ582423A (me) |
| PL (2) | PL2500014T5 (me) |
| PT (2) | PT2500014T (me) |
| RS (2) | RS58248B1 (me) |
| SI (2) | SI2164467T1 (me) |
| TN (1) | TN2009000476A1 (me) |
| UA (1) | UA99830C2 (me) |
| WO (1) | WO2008149320A2 (me) |
| ZA (1) | ZA200907940B (me) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI2500014T4 (fi) | 2007-06-06 | 2025-04-08 | Debiopharm Int Sa | Mikropartikkeleista valmistettu hitaasti vapauttava farmaseuttinen koostumus |
| PT105270B (pt) | 2010-08-26 | 2012-05-31 | Domino Ind Ceramicas S A | Camada de sílica com libertação lenta de fragrância, telha cerâmica e respectivo processo de produção |
| CN105267153B (zh) * | 2015-11-27 | 2018-05-11 | 上海苏豪逸明制药有限公司 | 一种曲普瑞林缓释微粒及其制备方法 |
| CN105797134B (zh) * | 2016-03-29 | 2019-06-14 | 浙江圣兆药物科技股份有限公司 | 一种难溶亮丙瑞林缓释制剂 |
| WO2018083633A1 (en) | 2016-11-02 | 2018-05-11 | Debiopharm International, S.A. | Methods for improving anti-cd37 immunoconjugate therapy |
| KR102402639B1 (ko) | 2017-11-24 | 2022-05-26 | 삼성전자주식회사 | 전자 장치 및 그의 통신 방법 |
| CN111000798B (zh) * | 2019-12-26 | 2021-11-23 | 四川恒博生物科技有限公司 | 一种采用原位凝胶技术的犬用非手术去势注射液 |
| IT202000017191A1 (it) | 2020-07-15 | 2022-01-15 | Xbrane Biopharma Ab | Procedimento senza acqua per preparare una composizione farmaceutica per un rilascio più prolungato e controllato di triptorelina o di un suo sale |
| WO2025017533A1 (en) | 2023-07-20 | 2025-01-23 | Ferring B.V. | Extended release drug-loaded microparticles |
| AR134273A1 (es) * | 2023-11-08 | 2025-12-17 | Debiopharm Int Sa | Triptorelina 12 meses |
| CN121401211A (zh) * | 2024-02-29 | 2026-01-27 | 珠海市华海康医药科技有限责任公司 | 一种双羟萘酸盐药物缓释微球及其制备方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0190833B1 (en) | 1985-02-07 | 1991-03-27 | Takeda Chemical Industries, Ltd. | Method for producing microcapsule |
| US4897268A (en) * | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| GB2209937B (en) | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
| US5225205A (en) * | 1989-07-28 | 1993-07-06 | Debiopharm S.A. | Pharmaceutical composition in the form of microparticles |
| CH679207A5 (me) | 1989-07-28 | 1992-01-15 | Debiopharm Sa | |
| MY107937A (en) | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
| CH683149A5 (fr) | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
| FR2693905B1 (fr) * | 1992-07-27 | 1994-09-02 | Rhone Merieux | Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues. |
| JP3277342B2 (ja) | 1992-09-02 | 2002-04-22 | 武田薬品工業株式会社 | 徐放性マイクロカプセルの製造法 |
| ATE223702T1 (de) * | 1993-10-22 | 2002-09-15 | Genentech Inc | Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien |
| US5945128A (en) * | 1996-09-04 | 1999-08-31 | Romano Deghenghi | Process to manufacture implants containing bioactive peptides |
| MY118835A (en) * | 1997-04-18 | 2005-01-31 | Ipsen Pharma Biotech | Sustained release compositions and the process for their preparation |
| JP2001522812A (ja) * | 1997-11-07 | 2001-11-20 | カイロン コーポレイション | Ｉｇｆ−１持続放出性処方物の作製方法 |
| TW200800298A (en) * | 2000-01-27 | 2008-01-01 | Zentaris Ag | Compressed microparticles for dry injection |
| US20040170665A1 (en) † | 2000-06-02 | 2004-09-02 | Allergan, Inc. | Intravitreal botulinum toxin implant |
| WO2003030870A1 (fr) * | 2001-10-10 | 2003-04-17 | Pierre Fabre Medicament | Microspheres biodegradables a liberation prolongee et leur procede de preparation |
| MXPA05011299A (es) * | 2003-04-30 | 2006-01-24 | Debiopharm Sa | Metodos y composiciones utilizando la hormona liberadora de la hormona gonadotropina. |
| KR100466637B1 (ko) * | 2003-06-26 | 2005-01-13 | 주식회사 펩트론 | 서방성 미립구의 혼합 제형을 연속한 단일 공정으로제조하는 방법 |
| FR2865938B1 (fr) * | 2004-02-05 | 2006-06-02 | Sod Conseils Rech Applic | Formulation retard solide comprenant de l'acetate de triptoreline |
| EP1968549B1 (en) | 2005-12-22 | 2014-05-14 | Novartis AG | Sustained release formulation comprising octreotide and two or more polylactide-co-glycolide polymers |
| FI2500014T4 (fi) | 2007-06-06 | 2025-04-08 | Debiopharm Int Sa | Mikropartikkeleista valmistettu hitaasti vapauttava farmaseuttinen koostumus |
-
2008
- 2008-06-06 FI FIEP12172232.6T patent/FI2500014T4/fi active
- 2008-06-06 AP AP2009005088A patent/AP3000A/xx active
- 2008-06-06 NZ NZ582423A patent/NZ582423A/en unknown
- 2008-06-06 HR HRP20161785TT patent/HRP20161785T1/hr unknown
- 2008-06-06 MY MYPI20094886 patent/MY150450A/en unknown
- 2008-06-06 CN CN200880018833.3A patent/CN101677959B/zh active Active
- 2008-06-06 EP EP12172232.6A patent/EP2500014B2/en active Active
- 2008-06-06 KR KR1020107000176A patent/KR101631475B1/ko active Active
- 2008-06-06 RS RS20181349A patent/RS58248B1/sr unknown
- 2008-06-06 LT LTEP12172232.6T patent/LT2500014T/lt unknown
- 2008-06-06 SI SI200831754A patent/SI2164467T1/sl unknown
- 2008-06-06 LT LTEP08763237.8T patent/LT2164467T/lt unknown
- 2008-06-06 PT PT12172232T patent/PT2500014T/pt unknown
- 2008-06-06 ES ES12172232T patent/ES2694401T5/es active Active
- 2008-06-06 BR BRPI0812250A patent/BRPI0812250B8/pt active IP Right Grant
- 2008-06-06 HU HUE12172232A patent/HUE040391T2/hu unknown
- 2008-06-06 PT PT87632378T patent/PT2164467T/pt unknown
- 2008-06-06 SI SI200832014T patent/SI2500014T2/sl unknown
- 2008-06-06 WO PCT/IB2008/052241 patent/WO2008149320A2/en not_active Ceased
- 2008-06-06 EP EP18186642.7A patent/EP3431077A1/en active Pending
- 2008-06-06 AU AU2008259411A patent/AU2008259411B2/en active Active
- 2008-06-06 HR HRP20181854TT patent/HRP20181854T4/hr unknown
- 2008-06-06 UA UAA200913838A patent/UA99830C2/uk unknown
- 2008-06-06 CA CA2688478A patent/CA2688478C/en active Active
- 2008-06-06 ES ES08763237.8T patent/ES2611020T3/es active Active
- 2008-06-06 HU HUE08763237A patent/HUE031550T2/en unknown
- 2008-06-06 RS RS20170032A patent/RS55591B1/sr unknown
- 2008-06-06 EP EP08763237.8A patent/EP2164467B1/en not_active Revoked
- 2008-06-06 EA EA200971132A patent/EA019284B1/ru unknown
- 2008-06-06 PL PL12172232.6T patent/PL2500014T5/pl unknown
- 2008-06-06 PL PL08763237T patent/PL2164467T3/pl unknown
- 2008-06-06 DK DK12172232.6T patent/DK2500014T4/da active
- 2008-06-06 JP JP2010510946A patent/JP5419169B2/ja active Active
- 2008-06-06 DK DK08763237.8T patent/DK2164467T3/en active
- 2008-06-06 ME MEP-2009-341A patent/ME00959B/me unknown
- 2008-06-06 US US12/601,649 patent/US10166181B2/en active Active
- 2008-06-06 MX MX2009012856A patent/MX2009012856A/es active IP Right Grant
-
2009
- 2009-11-09 TN TNP2009000476A patent/TN2009000476A1/fr unknown
- 2009-11-11 ZA ZA200907940A patent/ZA200907940B/xx unknown
- 2009-12-01 MA MA32391A patent/MA31422B1/fr unknown
- 2009-12-02 CO CO09137855A patent/CO6251234A2/es not_active Application Discontinuation
- 2009-12-03 IL IL202501A patent/IL202501A/en active IP Right Grant
-
2017
- 2017-01-17 CY CY20171100060T patent/CY1118434T1/el unknown
-
2018
- 2018-11-07 CY CY181101171T patent/CY1120891T1/el unknown
- 2018-11-15 US US16/192,674 patent/US20190192423A1/en not_active Abandoned
-
2022
- 2022-09-15 US US17/932,621 patent/US20230082575A1/en not_active Abandoned
-
2024
- 2024-12-03 US US18/967,155 patent/US20250205148A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME00959B (me) | Farmaceutska kompozicija sa sporim oslobađanjem koja je formirana od mikročestica | |
| Rein et al. | Meloxicam-loaded solvent exchange-induced in situ forming beta-cyclodextrin gel and microparticle for periodontal pocket delivery | |
| Phaechamud et al. | Doxycycline hyclate-loaded bleached shellac in situ forming microparticle for intraperiodontal pocket local delivery | |
| EP1786400A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE CONTROLLED RELEASE OF BIOLOGICAL ACTIVE SUBSTANCES | |
| CN101669900A (zh) | 更高效的利普安聚合物释放制剂 | |
| CN1835734A (zh) | 对温度敏感的状态改变型水凝胶组合物及其生产方法 | |
| RS54100B1 (sr) | Supstanca korisna za lečenje poremećaja metabolizma lipida | |
| HRP20171718T1 (hr) | Termooblikovan, farmaceutski oblik doziranja otporan na mijenjanje koji sadrži cink | |
| MX2009002757A (es) | Formulacion de farmaco resistente al abuso. | |
| SI2579874T1 (en) | INJECTION LIQUID COMPONENTS, EXPLOSIVE BUPRENORPHIN | |
| HRP20120766T4 (hr) | Formulacija za isporuku lijeka u kolonu | |
| TN2009000197A1 (en) | Sustained - release composition and method for producing the same | |
| RS55190B1 (sr) | Antipsihotička injektabilna deponujuća kompozicija | |
| CN100404022C (zh) | 用于皮肤贴膏的粘合剂组合物及其制造方法 | |
| WO2009145594A3 (ko) | 약물전달체 | |
| CN103142990B (zh) | 一种治疗畜禽细菌性疾病的药物及其制备方法 | |
| CN101966157B (zh) | 一种地西他滨缓释微球及其制备方法 | |
| Mahadlek et al. | Clotrimazole-loaded fatty acid-based in situ forming film oral spray | |
| AU2009208152A1 (en) | Improved composition for the topical transmission of active ingredients into the human or animal body | |
| Maskare et al. | Formulation of Microsponge of Thyme for Acne Treatment | |
| CN101053555B (zh) | 一种巴布剂基质及其制备方法 | |
| RS49840B (sr) | Tečne polimerne smeše za kontrolisano oslobađanje bioaktivnih supstanci | |
| CN101077340B (zh) | 促渗形巴布剂基质 | |
| CHUENBARN et al. | Development and mechanistic transformation of antimicrobial agent-loaded in-situ forming gel and microparticle using Eudragit RS and rosin as matrix formers for periodontal pocket delivery | |
| Niedrist | A granular hydrogel platform for periodontal applications |